What Is Venlafaxine Prescribed For: Depression, Anxiety

Venlafaxine is prescribed primarily for major depressive disorder and generalized anxiety disorder, though its reach extends well beyond those two conditions. Sold under the brand name Effexor (among others), it belongs to a class of medications called serotonin-norepinephrine reuptake inhibitors, or SNRIs, and that dual action on two brain chemicals is what makes it useful across a surprisingly wide range of problems. The full picture of what venlafaxine can treat, what side effects to expect, and why stopping it can be so difficult is worth understanding before you start or adjust this medication.

How Venlafaxine Works in the Brain

Most antidepressants work by keeping certain chemical messengers active in the brain for longer. Venlafaxine does this with two messengers at once: serotonin and norepinephrine. At lower doses, it acts mainly on serotonin, functioning much like an SSRI. As the dose increases, it begins to block the reuptake of norepinephrine too, giving it a broader neurochemical profile. Research in healthy volunteers confirmed this dose-dependent pattern: at lower doses, venlafaxine blocked most serotonin reuptake (about 87%), while at higher doses that figure climbed to 97% and the norepinephrine effects became more apparent.¹

Your body processes venlafaxine primarily through a liver enzyme called CYP2D6, which converts it into an active metabolite called O-desmethylvenlafaxine (the same compound sold separately as the drug desvenlafaxine).² Both the parent drug and this metabolite are pharmacologically active, which means venlafaxine keeps working even as your body breaks it down. This matters because people vary in how efficiently their CYP2D6 enzyme works, something that can influence side effects.

Treating Depression

Depression is the condition venlafaxine was originally developed to treat, and the evidence base here is deep. A meta-analysis of randomized controlled trials found that the extended-release formulation achieved remission in roughly 74% of patients, compared with about 61% for SSRIs and 58% for older tricyclic antidepressants.³ A separate meta-analysis looking at venlafaxine versus all SSRIs found a more modest but still statistically meaningful edge, with venlafaxine associated with higher odds of both response and remission.⁴

Those numbers sound impressive, but the real-world advantage over other antidepressants may be smaller than early studies suggested. The large STAR*D trial, which tracked what happened when patients who did not respond to the SSRI citalopram were switched to something else, found that venlafaxine, bupropion, and sertraline all produced similar remission rates: roughly one in four patients improved regardless of which medication they were switched to.⁵ More recent meta-analyses have found that the advantage of venlafaxine over SSRIs, where it exists, amounts to perhaps a 5-7% difference in response rates, far smaller than early enthusiasts hoped.⁶

Venlafaxine also appears effective at preventing depression from coming back. Compared with placebo, the odds of relapse with ongoing venlafaxine treatment were reduced by about 63%.⁴ That relapse-prevention benefit is a major reason doctors keep patients on the drug for months or years after an initial episode resolves.

Generalized Anxiety Disorder

Generalized anxiety disorder (GAD) is one of the conditions for which venlafaxine has been most thoroughly studied and is formally approved. Unlike situational anxiety that flares around specific events, GAD involves persistent, excessive worry about everyday life that is difficult to control and often accompanied by physical symptoms like muscle tension and poor sleep.

In a six-month randomized trial involving nondepressed outpatients with GAD, venlafaxine XR produced response rates of 69% or higher from week six onward, compared with 42-46% for placebo.⁷ Anxiety scores improved significantly starting in the first week or two of treatment and continued improving through the full 28 weeks of the trial. A separate eight-week trial confirmed that multiple dose levels of venlafaxine XR were effective and well tolerated in patients with GAD who did not have major depression.⁸

These results have held up across populations. A randomized, placebo-controlled trial in Japanese patients with GAD found a significant reduction in anxiety scores at eight weeks with venlafaxine ER, along with improvements in functional disability that went beyond just symptom control.⁹ The fact that venlafaxine works for anxiety independently of its antidepressant effect is clinically useful, because anxiety and depression often travel together and a single medication that addresses both can simplify treatment.

Panic Disorder and Social Anxiety

Beyond GAD, venlafaxine has shown effectiveness against panic disorder. In 12-week trials, venlafaxine XR was significantly more effective than placebo at achieving a panic-free state, with 54-70% of patients becoming panic-free on the drug compared with 34-48% on placebo.¹⁰ In a six-month follow-up study, relapse rates were dramatically lower in patients who continued venlafaxine XR compared with those switched to placebo (about 22% versus 50%). Venlafaxine was as effective as paroxetine, a commonly prescribed SSRI for panic, and it improved quality of life and daily functioning in addition to reducing panic attacks.¹¹

Social anxiety disorder is another approved indication. The same dual mechanism that helps with GAD and depression appears to ease the intense fear of social scrutiny that defines social anxiety, though the evidence base for this use gets less attention in the literature than the GAD and panic data.

Post-Traumatic Stress Disorder

Venlafaxine is not officially approved for PTSD in most countries, but it is frequently prescribed off-label and backed by solid trial data. A six-month randomized trial in men and women with diverse trauma types found that venlafaxine ER produced a remission rate of about 51%, compared with roughly 38% for placebo, with improvements in re-experiencing and avoidance symptoms, resilience, quality of life, and overall functioning.¹²

A separate 12-week trial directly compared venlafaxine ER, sertraline, and placebo in 538 PTSD patients. Venlafaxine was the only medication to significantly outperform placebo on the primary outcome measure, with a remission rate of about 30% versus roughly 20% for placebo; sertraline fell between the two and did not reach statistical significance.¹³ Those remission rates may sound low in absolute terms, but PTSD is notoriously difficult to treat pharmacologically, and the difference was clinically meaningful.

Neuropathic Pain

Venlafaxine is not licensed for chronic pain in most countries, but it is used off-label for neuropathic pain, the kind of burning, shooting, or tingling pain caused by nerve damage.¹⁴ The rationale is that norepinephrine plays a role in the brain’s descending pain-inhibition pathways, and venlafaxine’s dual-action mechanism can modulate those pathways at higher doses.

A systematic review found that in most studies, venlafaxine produced a clinically significant reduction in neuropathic pain compared with placebo, and that higher doses (around 150 mg per day) appeared more beneficial than lower ones.¹⁵ One of the most compelling individual trials looked at painful diabetic neuropathy and found a 50% reduction in pain intensity scores at the higher dose, compared with 27% for placebo.¹⁶ This makes venlafaxine a reasonable option when a patient has both depression and chronic pain, since one medication can address both.

Migraine Prevention and Hot Flashes

Two other off-label uses deserve mention because they are common enough that you may encounter them in practice. Venlafaxine has shown effectiveness in migraine prevention, reducing the frequency of migraines from roughly 16 to 11 per month in one study and performing comparably to amitriptyline, a traditional migraine-prevention drug, with fewer side effects.¹⁷¹⁸ A placebo-controlled trial confirmed it was safe and effective as migraine prophylaxis.¹⁹

Venlafaxine is also prescribed to reduce hot flashes, particularly in women who cannot take hormone replacement therapy because of a history of breast cancer. A randomized controlled trial in women with breast cancer found it was an effective non-hormonal option for managing hot flashes, though the benefit needed to be weighed against side effects.²⁰ Broader reviews of non-hormonal therapies for menopause have confirmed that venlafaxine reduces both the frequency and severity of vasomotor symptoms.²¹

Side Effects Worth Knowing About

Venlafaxine shares many side effects with SSRIs: nausea, headache, dizziness, insomnia, and drowsiness are all common, especially in the first few weeks. The extended-release formulation causes less nausea and dizziness than the immediate-release version, which is one reason XR has become the default.²²

Sexual dysfunction is a frequent complaint. In a naturalistic study, roughly 55% of patients taking venlafaxine reported some form of sexual side effect, a rate similar to paroxetine and citalopram and considerably higher than mirtazapine.²³ A large pharmacovigilance analysis confirmed that venlafaxine is associated with a range of sexual problems including difficulty reaching orgasm, delayed ejaculation, erectile dysfunction, and decreased libido.²⁴

Blood pressure deserves monitoring, especially at higher doses. A meta-analysis of over 3,700 patients found that the blood-pressure-raising effect of venlafaxine is highly dose-dependent and only becomes clinically significant at doses above 300 mg per day.²⁵ At typical therapeutic doses for depression and anxiety (75-225 mg), the risk of hypertension is modest, but case reports of accelerated hypertension at high doses exist.²⁶ Your doctor should check your blood pressure periodically while you are on this medication.

Why Stopping Venlafaxine Is Notoriously Difficult

If there is one thing venlafaxine is famous for among patients, it is how unpleasant it can be to stop taking. Roughly one in three patients on any antidepressant monotherapy develops withdrawal symptoms after discontinuation, but rates are higher with venlafaxine than with most other antidepressants.²⁷ Symptoms include so-called “brain zaps” (brief electrical-shock-like sensations in the head), dizziness, nausea, irritability, and heightened emotional volatility. For a substantial minority of patients, these symptoms persist for weeks and interfere with daily life.

The reason venlafaxine is particularly prone to withdrawal is partly pharmacological: it has a relatively short half-life, meaning its levels drop quickly once you miss a dose. Even a few hours’ delay can trigger symptoms in sensitive individuals. The standard medical advice is to taper gradually, often over weeks or months, reducing the dose in small increments. Patients who have been on venlafaxine for a long time may need an especially slow taper. If you are considering stopping, work closely with your prescriber rather than discontinuing abruptly.

Safety in Overdose

One area where venlafaxine compares unfavorably to SSRIs is in overdose. Reviews of deliberate self-poisoning data show a marginally higher toxicity profile for venlafaxine compared with SSRIs and duloxetine (another SNRI), though some of this difference may reflect the fact that venlafaxine tends to be prescribed to patients with more severe or treatment-resistant illness, who carry higher baseline risk.²⁸ In studies of self-poisoning episodes, patients who ingested venlafaxine were more likely to show signs of serious toxicity, including confusion, compared with SSRI overdoses.²⁹ This is a factor clinicians weigh when prescribing to patients at elevated suicide risk, and it is one reason SSRIs are often tried first.

Pregnancy Considerations

Venlafaxine use during early pregnancy has been linked to an increased risk of certain birth defects, including heart defects, cleft palate, and abdominal wall defects, in a large U.S. study spanning a decade.³⁰ A review of FDA adverse-event reports found venlafaxine at the top of the list of psychotropic medications associated with neonatal congenital anomalies.³¹

Even when no structural birth defects occur, newborns exposed to venlafaxine (or SSRIs) in utero often show transient behavioral symptoms in the first days of life. Central nervous system signs appeared in about 63% of exposed infants and respiratory symptoms in about 41%, though these typically resolved within three to five days.³² Premature newborns appeared more vulnerable, with longer hospital stays compared to unexposed preemies. None of this means venlafaxine can never be used during pregnancy; untreated severe depression carries its own serious risks to both mother and baby. But the decision requires a careful conversation between patient and prescriber about the specific risk-benefit balance.

How Your Genes Affect Your Response

Because CYP2D6 is the main enzyme that metabolizes venlafaxine, your genetic version of that enzyme can meaningfully influence how the drug behaves in your body. People with reduced CYP2D6 function (so-called poor metabolizers) end up with higher blood levels of venlafaxine and its active metabolite, while ultra-rapid metabolizers clear the drug faster than average.³³

What does this mean practically? Patients who are poor metabolizers tend to experience more side effects, particularly gastrointestinal ones like nausea and vomiting.³⁴ Interestingly, though, systematic reviews and meta-analyses have not found a clear link between CYP2D6 status and how well venlafaxine works against depression.³⁵ In other words, poor metabolizers get more side effects but not necessarily better antidepressant results. Pharmacogenomic testing for CYP2D6 is available and can inform dosing decisions, particularly if you have had unusual reactions to medications metabolized by the same enzyme in the past.

When an SSRI Has Not Worked

A common clinical scenario is the patient whose first antidepressant, usually an SSRI, has not worked well enough. Doctors often consider venlafaxine as a next step, reasoning that its broader mechanism might succeed where a serotonin-only drug did not. A meta-analysis of switching strategies found that patients who switched to a non-SSRI antidepressant (including venlafaxine) were modestly more likely to achieve remission than those who simply tried a different SSRI, with pooled remission rates of about 28% versus 23.5%.³⁶

That advantage, while real, is modest. And there was a trend toward slightly more people dropping out due to intolerance when switching to a non-SSRI. In adolescents with SSRI-resistant depression, venlafaxine was not superior to switching to another SSRI, and the slightly higher rate of cardiovascular effects led researchers to recommend trying a second SSRI first in that age group.⁶ For adults, the STAR*D trial’s finding that venlafaxine, bupropion, and sertraline performed similarly as second-step options suggests that the “right” switch depends as much on a patient’s individual side-effect profile and preferences as on any inherent superiority of one drug over another.⁵

1
Archives of General Psychiatry. Evidence of the Dual Mechanisms of Action of Venlafaxine
2
PubMed. Enantioselective Pharmacokinetics of Venlafaxine in the Presence of CYP2D6 Inhibition
3
Clinical Therapeutics. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression
4
PubMed. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression
5
PubMed. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression
6
JAMA. Switching to Another SSRI or to Venlafaxine With or Without Cognitive Behavioral Therapy for Adolescents With SSRI-Resistant Depression
7
PubMed. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder
8
PubMed. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
9
PubMed Central. A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release in Japanese patients with generalized anxiety disorder
10
PubMed Central. Venlafaxine extended release (XR) in the treatment of panic disorder
11
PubMed Central. Venlafaxine in the treatment of panic disorder
12
JAMA Psychiatry. Treatment of Posttraumatic Stress Disorder With Venlafaxine Extended Release
13
Journal of Clinical Psychopharmacology. Venlafaxine Extended Release in Posttraumatic Stress Disorder
14
PubMed Central. Venlafaxine for neuropathic pain in adults
15
Pain Medicine. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review
16
PubMed. Venlafaxine extended release in the treatment of painful diabetic neuropathy
17
PubMed. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache
18
PubMed. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine
19
PubMed. The efficacy and safety of venlafaxine in the prophylaxis of migraine
20
The Lancet. Venlafaxine in the management of hot flashes in women with breast cancer
21
PubMed Central. Nonhormonal Pharmacotherapies for the Treatment of Postmenopausal Vasomotor Symptoms
22
PubMed Central. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression
23
PubMed Central. Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting
24
Sexual Medicine. Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction
25
PubMed. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients
26
PubMed Central. Accelerated hypertension after venlafaxine usage
27
PubMed Central. Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine
28
PubMed Central. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care
29
PubMed Central. A comparison of venlafaxine and SSRIs in deliberate self-poisoning
30
PubMed Central. The Association Between Reported Venlafaxine Use in Early Pregnancy and Birth Defects, National Birth Defects Prevention Study, 1997–2007
31
PubMed. Risk of congenital anomalies associated with psychotropic medications
32
Pediatrics. Effects of Selective Serotonin Reuptake Inhibitors and Venlafaxine During Pregnancy in Term and Preterm Neonates
33
PubMed. CYP2D6 Phenotype Influences Pharmacokinetic Parameters of Venlafaxine
34
PubMed. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
35
PubMed. The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine
36
PubMed. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches